NASDAQ:BBI

Brickell Biotech (BBI) Stock Forecast, Price & News

$0.98

+0.04 (+4.26%)

(As of 09/22/2023 ET)

Compare

Today's Range: $0.90
▼
$1.00
50-Day Range: $0.58
▼
$0.98
52-Week Range: $2.21
▼
$37.35

Volume: 621,334 shs
Average Volume: 206,730 shs
Market Capitalization: $2.82 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Chart Competitors Financials Institutional Ownership Headlines SEC Filings Short Interest Social Media

About Brickell Biotech (NASDAQ:BBI) Stock

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.

BBI Price History

30 days | 90 days | 365 days | Advanced Chart

BBI Stock News Headlines

August 27, 2023 | dailymail.co.uk

Paul Simon and Edie Brickell's daughter speaks out following parents' arrest

April 25, 2023 | bizjournals.com

Seattle Biotech News

September 24, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

April 10, 2023 | marketwatch.com

Nuclear Receptor ROR-Gamma Market Size by 2030

March 29, 2023 | travel.usnews.com

Brickell City Centre

March 24, 2023 | bizjournals.com

Biotech News

March 18, 2023 | techcrunch.com

5 strategies for biotech startups to outlast a market downturn

March 14, 2023 | marketwatch.com

Nuclear Receptor ROR-Gamma Market Application, Product, Sales and Forecast 2023-2028

September 24, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

February 27, 2023 | finance.yahoo.com

What Sunzen Biotech Berhad's (KLSE:SUNZEN) P/E Is Not Telling You

February 27, 2023 | techcrunch.com

Biotech proved a surprisingly bright spot in 2022’s startup correction

February 21, 2023 | msn.com

Paul Simon Was 50 When He Married a 26-Year-Old Edie Brickell

February 19, 2023 | cnbc.com

This biotech hedge fund has elite clients like Yale’s endowment, Tisch. Here are its top bets

February 10, 2023 | benzinga.com

Best Biotech Penny Stocks

January 13, 2023 | markets.businessinsider.com

VERO Biotech Raises $30 Million to Accelerate Commercialization of Its Innovative Tankless Inhaled Nitric Oxide Delivery System

January 9, 2023 | cbsnews.com

USDA approves vaccine for honeybees, biotech company says

January 4, 2023 | marketwatch.com

Bioreactors and Fermenters Market 2023 Expected to Witness the Highest Revenue Growth Over Forecast to 2028

December 28, 2022 | forbes.com

Brickell Biotech

December 18, 2022 | marketwatch.com

Nuclear Receptor ROR-Gamma Market : Industry Analysis 2023 To 2028 based on Sales, Revenue, Size and Share

December 5, 2022 | nz.finance.yahoo.com

Atopic Dermatitis Pipeline Appears Robust With 90+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

September 13, 2022 | finance.yahoo.com

Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of DYRK1A Inhibitor FRTX-02

September 7, 2022 | finance.yahoo.com

Brickell Biotech Announces Corporate Rebranding to Fresh Tracks Therapeutics

August 11, 2022 | seekingalpha.com

Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q2 2022 Results - Earnings Call Transcript

August 2, 2022 | benzinga.com

Brickell Biotech to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on August 11, 2022

July 20, 2022 | finance.yahoo.com

Brickell Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement

July 6, 2022 | finance.yahoo.com

Brickell Biotech to Participate at William Blair Biotech Focus Conference 2022

July 1, 2022 | marketwatch.com

Brickell Biotech Shares Down 24% After Reverse Stock Split Plans

See More Headlines

Receive BBI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Brickell Biotech and its competitors with MarketBeat's FREE daily newsletter.

BBI Company Calendar

Last Earnings: 8/11/2022
Today: 9/24/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological Products, Except Diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BBI
CUSIP: N/A
CIK: 819050
Web: www.brickellbio.com
Phone: (720) 505-4755
Fax: 858-646-1150
Employees: 16
Year Founded: 2009

Profitability

EPS (Most Recent Fiscal Year): ($13.52)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-39,470,000.00
Net Margins: -643.48%
Pretax Margin: -643.48%
Return on Equity: -156.10%
Return on Assets: -128.23%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.36
Quick Ratio: 6.36

Sales & Book Value

Annual Sales: $4.64 million
Price / Sales: 0.61
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $9.75 per share
Price / Book: 0.10

Miscellaneous

Outstanding Shares: 2,874,000
Free Float: 2,744,000
Market Cap: $2.82 million
Optionable: Not Optionable
Beta: 0.02

Social Links

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Reginald L. Hardy M.B.A. (Age 64)
R.Ph., Co-Founder & Chairman
Comp: $76.83k

Attorney Robert Busard Brown (Age 60)
CEO & Director
Comp: $816.73k

Mr. Andrew D. Sklawer (Age 38)
Co-Founder, Pres, COO & Sec.
Comp: $559.58k

Mr. Deepak Chadha M.B.A. (Age 52)
M.S., MBA, MS, RAC, Chief R&D Officer
Comp: $543.59k

Mr. Albert Nicholas Marchio II (Age 70)
CFO and Principal Accounting & Financial Officer

Mr. David R. Mcavoy J.D. (Age 59)
Gen. Counsel & Chief Compliance Officer

Mr. Gary S. Walker (Age 62)
Chief Marketing Officer

Aron Aizenstat M.B.A.
P.M.P., VP of Corp. Devel. & Operations

Ms. Sue Fattor
Head of Human Resource

Ms. Nancy Seretta
VP & Head of Clinical Operations

Key Competitors

View All Competitors

BBI Stock - Frequently Asked Questions

How have BBI shares performed in 2023?: Brickell Biotech's stock was trading at $1.50 on January 1st, 2023. Since then, BBI stock has decreased by 34.7% and is now trading at $0.98.
View the best growth stocks for 2023 here.
How were Brickell Biotech's earnings last quarter?: Brickell Biotech, Inc. (NASDAQ:BBI) released its quarterly earnings results on Thursday, August, 11th. The company reported ($0.01) earnings per share for the quarter, beating analysts' consensus estimates of ($1.48) by $1.47. Brickell Biotech had a negative net margin of 643.48% and a negative trailing twelve-month return on equity of 156.10%. During the same period in the previous year, the business earned ($7.21) earnings per share.
When did Brickell Biotech's stock split?: Brickell Biotech shares reverse split on the morning of Tuesday, July 5th 2022. The 1-45 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.
What other stocks do shareholders of Brickell Biotech own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Brickell Biotech investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (vbiv), Jaguar Health (JAGX), Miragen Therapeutics (MGEN), Acasti Pharma (ACST), Allena Pharmaceuticals (ALNA), Aileron Therapeutics (ALRN), Amarin (AMRN), Fortress Biotech (FBIO) and iBio (IBIO).

What is Brickell Biotech's stock symbol?: Brickell Biotech trades on the NASDAQ under the ticker symbol "BBI."
How do I buy shares of Brickell Biotech?: Shares of BBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Brickell Biotech's stock price today?: One share of BBI stock can currently be purchased for approximately $0.98.
How much money does Brickell Biotech make?: Brickell Biotech (NASDAQ:BBI) has a market capitalization of $2.82 million and generates $4.64 million in revenue each year. The company earns $-39,470,000.00 in net income (profit) each year or ($13.52) on an earnings per share basis.
How can I contact Brickell Biotech?: Brickell Biotech's mailing address is 5777 CENTRAL AVENUE SUITE 102, BOULDER CO, 80301. The official website for the company is www.brickellbio.com. The company can be reached via phone at (720) 505-4755, via email at ir@brickellbio.com, or via fax at 858-646-1150.

This page (NASDAQ:BBI) was last updated on 9/24/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial